2017 Q2 Form 10-Q Financial Statement
#000114420417027041 Filed on May 15, 2017
Income Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $640.0K | $830.0K | $830.0K |
| YoY Change | -22.89% | 0.0% | -13.54% |
| % of Gross Profit | |||
| Research & Development | $435.0K | $941.0K | $990.0K |
| YoY Change | 188.08% | -4.95% | -20.48% |
| % of Gross Profit | |||
| Depreciation & Amortization | $18.00K | $16.00K | $16.00K |
| YoY Change | -18.18% | 0.0% | -20.0% |
| % of Gross Profit | |||
| Operating Expenses | $435.0K | $941.0K | $1.810M |
| YoY Change | 188.08% | -48.01% | -17.91% |
| Operating Profit | -$1.075M | -$1.770M | -$1.812M |
| YoY Change | 9.36% | -2.32% | -17.82% |
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $40.00K | -$20.00K | $20.00K |
| YoY Change | 100.0% | -200.0% | -166.67% |
| Pretax Income | -$1.040M | -$1.790M | -$1.790M |
| YoY Change | 8.33% | 0.0% | -20.09% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$1.040M | -$1.790M | -$1.790M |
| YoY Change | 8.11% | 0.0% | -19.95% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$55.50K | -$95.77K | -$95.98K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 18.74M shares | 18.65M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $6.720M | $8.350M | $12.95M |
| YoY Change | -41.46% | -35.52% | -39.34% |
| Cash & Equivalents | $5.784M | $604.0K | $2.213M |
| Short-Term Investments | $930.0K | $7.740M | $10.73M |
| Other Short-Term Assets | $230.0K | $180.0K | $80.00K |
| YoY Change | 228.57% | 125.0% | 100.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $740.0K | $200.0K | $480.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $7.680M | $8.730M | $13.51M |
| YoY Change | -40.05% | -35.38% | -38.81% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $300.0K | $280.0K | $281.0K |
| YoY Change | -5.66% | -0.36% | -3.1% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $20.00K | $30.00K | $304.0K |
| YoY Change | -94.13% | -90.13% | 1420.0% |
| Total Long-Term Assets | $320.0K | $300.0K | $304.0K |
| YoY Change | -6.98% | -1.32% | -1.62% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $7.680M | $8.730M | $13.51M |
| Total Long-Term Assets | $320.0K | $300.0K | $304.0K |
| Total Assets | $8.000M | $9.030M | $13.81M |
| YoY Change | -39.18% | -34.63% | -38.29% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $230.0K | $360.0K | $281.0K |
| YoY Change | -35.21% | 28.11% | -69.52% |
| Accrued Expenses | $114.0K | $90.00K | $675.0K |
| YoY Change | -82.52% | -86.67% | -57.03% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | |||
| Total Short-Term Liabilities | $711.0K | $789.0K | $1.242M |
| YoY Change | -44.54% | -36.47% | -54.44% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $711.0K | $789.0K | $1.242M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $710.0K | $790.0K | $1.240M |
| YoY Change | -44.53% | -36.29% | -54.51% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$77.95M | -$76.91M | -$71.93M |
| YoY Change | 6.93% | 6.92% | 12.59% |
| Common Stock | $11.00K | $85.15M | $11.00K |
| YoY Change | -99.99% | 774000.0% | -99.99% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $7.290M | $8.243M | $12.57M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $8.000M | $9.032M | $13.81M |
| YoY Change | -39.18% | -34.6% | -38.31% |
Cashflow Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.040M | -$1.790M | -$1.790M |
| YoY Change | 8.11% | 0.0% | -19.95% |
| Depreciation, Depletion And Amortization | $18.00K | $16.00K | $16.00K |
| YoY Change | -18.18% | 0.0% | -20.0% |
| Cash From Operating Activities | -$1.630M | -$1.640M | -$2.980M |
| YoY Change | 15.6% | -44.97% | 53.85% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $32.00K | $0.00 | $26.00K |
| YoY Change | -45.76% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $6.810M | $1.700M | $4.790M |
| YoY Change | 3305.0% | -64.51% | -135.3% |
| Cash From Investing Activities | $6.780M | $1.699M | $4.770M |
| YoY Change | 5115.38% | -64.38% | -135.16% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $30.00K | $0.00 | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -$1.630M | -1.640M | -2.980M |
| Cash From Investing Activities | $6.780M | $1.699M | 4.770M |
| Cash From Financing Activities | $30.00K | $0.00 | 0.000 |
| Net Change In Cash | $5.180M | $1.699M | 1.790M |
| YoY Change | -504.69% | -5.08% | -336.46% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.630M | -$1.640M | -$2.980M |
| Capital Expenditures | $32.00K | $0.00 | $26.00K |
| Free Cash Flow | -$1.662M | -$1.640M | -$3.006M |
| YoY Change | 13.14% | -45.44% | 55.19% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | us-gaap |
Accounts Payable Other Current
AccountsPayableOtherCurrent
|
337000 | USD |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
90000 | USD |
| CY2017Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
126000 | USD |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
789000 | USD |
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
85140000 | USD |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
11000 | USD |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-76908000 | USD |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8243000 | USD |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9032000 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14128000 | USD |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4982000 | USD |
| CY2017Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
0 | USD |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
16000 | USD |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
16000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1642000 | USD |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2981000 | USD |
| CY2017Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
126000 | USD |
| CY2016Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
203000 | USD |
| CY2017Q1 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
0 | USD |
| CY2016Q1 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
31000 | USD |
| CY2017Q1 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-76000 | USD |
| CY2016Q1 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-269000 | USD |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
26000 | USD |
| CY2017Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-1700000 | USD |
| CY2016Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-4794000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
57000 | USD |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1785000 | USD |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
428000 | USD |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2213000 | USD |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q1 | bcli |
Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
|
0.05 | pure |
| CY2017Q1 | bcli |
Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
|
P15Y | |
| CY2017Q1 | bcli |
Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
|
0.03 | pure |
| CY2017Q1 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P1M | |
| CY2016 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P6M | |
| CY2012Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4900000 | USD |
| CY2009Q4 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
74667 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
126000 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
234000 | USD |
| CY2017Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2017Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | |
| CY2017Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2017Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
BRAINSTORM CELL THERAPEUTICS INC. | |
| CY2017Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001137883 | |
| CY2017Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2017Q1 | dei |
Trading Symbol
TradingSymbol
|
BCLI | |
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
18735550 | shares |
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18699665 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18687987 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18699665 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18687987 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
14246831 | shares |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
4489973 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
3437988 | shares |
| CY2017Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
6318868 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
6318868 | shares |
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
46600000 | USD | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
17000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-888000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-822000 | USD |
